COVID-19 brings new challenges to pharmacovigilance teams as outdated and often disjointed processes are stressed by the incoming wave safety reports resulting from the accelerated approval of new treatments and the implementation of mass vaccination campaigns.
In this presentation, originally given at the World Drug Safety Conference Americas 2020, Dr Andrew Rut discusses the challenges of managing adverse event intake and processing in a fast-paced and high impact development cycle and outline how digital transformation of pharmacovigilance means we are better placed to manage post approval safety monitoring during the COVID-19 response.
